AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27678541 — intervention group
Group type: EXPERIMENTAL
Intervention: Human recombinant alkaline phosphatase (recAP)
Number of subjects: 290
Study 27678545 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole soy replacement diet (4 servings of whole soy foods containing 25g soy protein daily, replacing red or processed meat and high fat dairy products)
Number of subjects: 208
Study 27678545 — intervention group
Group type: COMPARATOR
Intervention: Usual diet (control group)
Number of subjects: 208
Study 27679799 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal capnography (TcCO2)
Number of subjects: 55
Study 27679799 — intervention group
Group type: COMPARATOR
Intervention: Nocturnal oxygen saturation monitoring (SpO2)
Number of subjects: 55
Study 27680716 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk containing only A2 type β-casein
Number of subjects: 0
Study 27680716 — intervention group
Group type: COMPARATOR
Intervention: Milk containing both A1 and A2 types of β-casein
Number of subjects: 0
Study 27680873 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous hydrocortisone infusion (CSHI)
Number of subjects: 8
Study 27680873 — intervention group
Group type: COMPARATOR
Intervention: Conventional oral glucocorticoid treatment
Number of subjects: 8
Study 27680875 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (GnRHa) - leuprolide 3.75-mg administered for 4 weeks
Number of subjects: 29
Study 27680875 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 29
Study 27680993 — intervention group
Group type: EXPERIMENTAL
Intervention: Total potato consumption (3 servings/week increment)
Number of subjects: 69313
Study 27680996 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher adherence to the Mediterranean diet (aMED)
Number of subjects: 4470
Study 27681000 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Number of subjects: 16492
Study 27681711 — intervention group
Group type: EXPERIMENTAL
Intervention: Interest circle calls
Number of subjects: 201
Study 27681711 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning sessions
Number of subjects: 201
Study 27681711 — intervention group
Group type: EXPERIMENTAL
Intervention: Coach only
Number of subjects: 201
Study 27681711 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of all three strategies
Number of subjects: 201
Study 27681799 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactoferrin (LF)
Number of subjects: 0
Study 27681799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27681866 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib 75 mg daily with sorafenib 400 mg twice daily
Number of subjects: 27
Study 27681866 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)
Number of subjects: 27
Study 27682440 — intervention group
Group type: EXPERIMENTAL
Intervention: HFpEF risk factors
Number of subjects: 42170
Study 27682440 — intervention group
Group type: EXPERIMENTAL
Intervention: HFpEF
Number of subjects: 42170
Study 27682440 — intervention group
Group type: EXPERIMENTAL
Intervention: HFrEF risk factors
Number of subjects: 42170
Study 27682582 — intervention group
Group type: EXPERIMENTAL
Intervention: Refeeding syndrome (RFS)
Number of subjects: 54
Study 27682582 — intervention group
Group type: EXPERIMENTAL
Intervention: Refeeding phenomena
Number of subjects: 54
Study 27682582 — intervention group
Group type: COMPARATOR
Intervention: Baseline characteristics
Number of subjects: 54
Study 27682602 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle variables, gastroenteritis episodes, dental hygiene, hazelnut cocoa spread consumption, wasp and bee stings, consumption of vegetables from a farm, death of a pet by old age
Number of subjects: 0
Study 27682602 — intervention group
Group type: COMPARATOR
Intervention: Control group (schoolmates or friends)
Number of subjects: 0
Study 27682742 — intervention group
Group type: EXPERIMENTAL
Intervention: MBDA score
Number of subjects: 52
Study 27683021 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring coaching system
Number of subjects: 0
Study 27683610 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled treprostinil
Number of subjects: 1333
Study 27683610 — intervention group
Group type: COMPARATOR
Intervention: Control (other FDA-approved PAH therapies)
Number of subjects: 1333
Study 27683850 — intervention group
Group type: EXPERIMENTAL
Intervention: APOE ε4 carriers
Number of subjects: 207
Study 27683850 — intervention group
Group type: COMPARATOR
Intervention: APOE ε4 noncarriers
Number of subjects: 207
Study 27683872 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 IU cholecalciferol/d
Number of subjects: 2753
Study 27683872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2753
Study 27685842 — intervention group
Group type: COMPARATOR
Intervention: edivoxetine 6-18 mg/d (monotherapy)
Number of subjects: 2561
Study 27685842 — intervention group
Group type: COMPARATOR
Intervention: edivoxetine (adjunctive treatment)
Number of subjects: 2561
Study 27685842 — intervention group
Group type: COMPARATOR
Intervention: edivoxetine (monotherapy)
Number of subjects: 2561
Study 27686326 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcirculatory flow and postcapillary venous oxygen saturation detected during vaso-occlusive testing (VOT)
Number of subjects: 20
Study 27686326 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcirculatory reserve as assessed by SvcO
Number of subjects: 20
Study 27686833 — intervention group
Group type: EXPERIMENTAL
Intervention: JE-CV vaccine in MBDV-primed 2-5-year-olds (n=78)
Number of subjects: 300
Study 27686833 — intervention group
Group type: EXPERIMENTAL
Intervention: JE-CV vaccine in JE-vaccine-naïve toddlers
Number of subjects: 300
Study 27686862 — intervention group
Group type: EXPERIMENTAL
Intervention: ISC-hpNSC (human parthenogenetic stem cell derived neural stem cells)
Number of subjects: 0
Study 27687127 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 g eicosapentaenoic acid + docosahexaenoic acid per day during low-fat diet phase
Number of subjects: 56
Study 27687127 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 g eicosapentaenoic acid + docosahexaenoic acid per day during habitual diet phase
Number of subjects: 56
Study 27687127 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet phase
Number of subjects: 56
Study 27687127 — intervention group
Group type: EXPERIMENTAL
Intervention: Habitual diet phase
Number of subjects: 56
Study 27687295 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive decision making about Pap tests
Number of subjects: 32
Study 27687295 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative decision making about Pap tests
Number of subjects: 32
Study 27687480 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib, lenalidomide and dexamethasone (CRd)
Number of subjects: 45
Study 27687632 — intervention group
Group type: EXPERIMENTAL
Intervention: Seva app implementation
Number of subjects: 53
Study 27687632 — intervention group
Group type: EXPERIMENTAL
Intervention: Seva app usage
Number of subjects: 53
Study 27687632 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring health tracking and relapses
Number of subjects: 53
Study 27687632 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation focus on behavioral health care providers
Number of subjects: 53
Study 27687632 — intervention group
Group type: EXPERIMENTAL
Intervention: Designated replacements for clinician turnover
Number of subjects: 53
Study 27689425 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative opioid use
Number of subjects: 93
Study 27689425 — intervention group
Group type: COMPARATOR
Intervention: No preoperative opioid use
Number of subjects: 93
Study 27689498 — intervention group
Group type: EXPERIMENTAL
Intervention: ¡Cuídate! intervention (n=1326)
Number of subjects: 2169
Study 27689498 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=870)
Number of subjects: 2169
Study 27689969 — intervention group
Group type: EXPERIMENTAL
Intervention: TARGeted Intraoperative radioTherapy (TARGIT)
Number of subjects: 3451
Study 27689969 — intervention group
Group type: COMPARATOR
Intervention: Whole-breast external beam radiotherapy (EBRT)
Number of subjects: 3451
Study 27689969 — intervention group
Group type: EXPERIMENTAL
Intervention: TARGIT
Number of subjects: 3451
Study 27689969 — intervention group
Group type: COMPARATOR
Intervention: EBRT
Number of subjects: 3451
Study 27690095 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional vitamin D treatment (0.25 mcg alfacalcidol plus placebo 3×/week)
Number of subjects: 56
Study 27690095 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive vitamin D treatment (0.25 mcg alfacalcidol 3×/week plus 50,000 IU ergocalciferol 1×/week)
Number of subjects: 56
Study 27692306 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct oral factor Xa inhibitors (rivaroxaban, apixaban, edoxaban)
Number of subjects: 178
Study 27692306 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct oral factor Xa inhibitors
Number of subjects: 178
Study 27692683 — intervention group
Group type: COMPARATOR
Intervention: Neither hypotension nor hypoxia
Number of subjects: 13151
Study 27692683 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotension only (systolic blood pressure <90 mm Hg)
Number of subjects: 13151
Study 27692683 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia only (saturation <90%)
Number of subjects: 13151
Study 27692683 — intervention group
Group type: EXPERIMENTAL
Intervention: Both hypotension and hypoxia
Number of subjects: 13151
Study 27692920 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-prostatic boost dose of 68 Gy
Number of subjects: 28
Study 27692920 — intervention group
Group type: COMPARATOR
Intervention: Standard radiotherapy (60 Gy in 20 fractions)
Number of subjects: 28
Study 27693420 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Training (ET) group (n=23)
Number of subjects: 47
Study 27693420 — intervention group
Group type: COMPARATOR
Intervention: Attention Control (AC) group (n=24)
Number of subjects: 47
Study 27693556 — intervention group
Group type: EXPERIMENTAL
Intervention: selinexor + dexamethasone (DEX)
Number of subjects: 0
Study 27693556 — intervention group
Group type: EXPERIMENTAL
Intervention: selinexor + everolimus (EVER)
Number of subjects: 0
Study 27693556 — intervention group
Group type: EXPERIMENTAL
Intervention: selinexor
Number of subjects: 0
Study 27693556 — intervention group
Group type: EXPERIMENTAL
Intervention: selinexor and related SINE compounds
Number of subjects: 0
Study 27693614 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Training (MT)
Number of subjects: 23
Study 27693614 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-Behavioral Treatment (FFS/CBT)
Number of subjects: 23
Study 27694141 — intervention group
Group type: EXPERIMENTAL
Intervention: HIF-2α inhibition by small hairpin RNA or selective small molecule antagonist
Number of subjects: 0
Study 27694141 — intervention group
Group type: COMPARATOR
Intervention: Acidic bile salts exposure in oesophageal cells
Number of subjects: 0
Study 27694141 — intervention group
Group type: COMPARATOR
Intervention: Patients developing RO
Number of subjects: 0
Study 27694312 — intervention group
Group type: EXPERIMENTAL
Intervention: thumb-ECG recordings
Number of subjects: 100
Study 27694312 — intervention group
Group type: COMPARATOR
Intervention: Holter monitoring
Number of subjects: 100
Study 27694312 — intervention group
Group type: EXPERIMENTAL
Intervention: thumb-ECG
Number of subjects: 100
Study 27694312 — intervention group
Group type: EXPERIMENTAL
Intervention: thumb-ECG and Holter monitoring
Number of subjects: 100
Study 27695088 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA prime/adenovirus boost malaria vaccine encoding Plasmodium falciparum strain 3D7 CSP and AMA1
Number of subjects: 0
Study 27695088 — intervention group
Group type: COMPARATOR
Intervention: 7G8 variant peptides
Number of subjects: 0
Study 27695119 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval walking consisting of repeated cycles of 3 min slow and 3 min fast walking (IW3)
Number of subjects: 12
Study 27695119 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval walking consisting of repeated cycles of 1 min slow and 1 min fast walking (IW1)
Number of subjects: 12
Study 27695119 — intervention group
Group type: COMPARATOR
Intervention: No walking (CON)
Number of subjects: 12
Study 27695130 — intervention group
Group type: EXPERIMENTAL
Intervention: mRDTs for malaria diagnosis
Number of subjects: 0
Study 27695130 — intervention group
Group type: COMPARATOR
Intervention: Clinical judgement
Number of subjects: 0
Study 27695295 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) administration of rituximab (MabThera)
Number of subjects: 1051
Study 27695295 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) administration of rituximab (MabThera)
Number of subjects: 1051
Study 27696335 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban plasma level measurement (RivLev)
Number of subjects: 38
Study 27696724 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab plus methotrexate (MTX)
Number of subjects: 0
Study 27696724 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX) alone
Number of subjects: 0
Study 27696724 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on infliximab
Number of subjects: 0
Study 27696724 — intervention group
Group type: COMPARATOR
Intervention: Add-on placebo
Number of subjects: 0
Study 27696724 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on golimumab
Number of subjects: 0
Study 27696739 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone metacarpophalangeal joint arthroplasty (SMPA)
Number of subjects: 0
Study 27696739 — intervention group
Group type: COMPARATOR
Intervention: Non-SMPA (medical management alone)
Number of subjects: 0
Study 27696739 — intervention group
Group type: EXPERIMENTAL
Intervention: SMPA
Number of subjects: 0
Study 27697769 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep dry needling (DN) of myofascial trigger points (MTrPs) in the masseter and temporalis.
Number of subjects: 17
Study 27697771 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab, lenalidomide, and ibrutinib
Number of subjects: 0
Study 27697849 — intervention group
Group type: EXPERIMENTAL
Intervention: Occipital nerve stimulation (ONS)
Number of subjects: 44
Study 27697877 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostering Open eXpression among Youth (FOXY) arts-based intervention
Number of subjects: 150
Study 27697882 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose consumption
Number of subjects: 125299
Study 27697952 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer crowd affiliation with Hip Hop
Number of subjects: 3368
Study 27697952 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer crowd affiliation with Hipster
Number of subjects: 3368
Study 27697952 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer crowd affiliation as a categorical predictor
Number of subjects: 3368
Study 27697952 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer crowd affiliation as a continuous predictor (Hip Hop)
Number of subjects: 3368
Study 27697952 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer crowd affiliation as a continuous predictor (Young Professional)
Number of subjects: 3368
Study 27697952 — intervention group
Group type: EXPERIMENTAL
Intervention: Antitobacco interventions targeting peer crowds
Number of subjects: 3368
Study 27698149 — intervention group
Group type: EXPERIMENTAL
Intervention: Febrile seizures group
Number of subjects: 192
Study 27698149 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 192
Study 27698676 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyeonggaeyeongyo-tang (HYT) for 4 weeks
Number of subjects: 0
Study 27699214 — intervention group
Group type: EXPERIMENTAL
Intervention: Early biopsies taken within 4 months after transplant
Number of subjects: 681
Study 27699214 — intervention group
Group type: EXPERIMENTAL
Intervention: Late biopsies taken after 4 months
Number of subjects: 681
Study 27699214 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular phenotype analysis of early biopsies
Number of subjects: 681
Study 27699214 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathway analysis of late biopsies
Number of subjects: 681
Study 27699214 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall findings regarding fibrosis progression
Number of subjects: 681
Study 27699252 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib citrate (5 mg) given twice daily for 3 months
Number of subjects: 66
Study 27699253 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ruxolitinib
Number of subjects: 0
Study 27699259 — intervention group
Group type: EXPERIMENTAL
Intervention: Index of Microvascular Resistance (IMR)
Number of subjects: 211
Study 27699259 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary Flow Reserve (CFR)
Number of subjects: 211
Study 27699259 — intervention group
Group type: EXPERIMENTAL
Intervention: IMR
Number of subjects: 211
Study 27699270 — intervention group
Group type: EXPERIMENTAL
Intervention: Asfotase alfa therapy
Number of subjects: 0
Study 27699405 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjunctival swab samples analyzed by bacterial culture and 16S rDNA gene deep sequencing
Number of subjects: 107
Study 27699405 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative 16S PCR
Number of subjects: 107
Study 27699405 — intervention group
Group type: EXPERIMENTAL
Intervention: Principal coordinate analysis of metagenomics data
Number of subjects: 107
Study 27699405 — intervention group
Group type: EXPERIMENTAL
Intervention: 16S metagenomics
Number of subjects: 107
Study 27699405 — intervention group
Group type: EXPERIMENTAL
Intervention: BRiSK analysis
Number of subjects: 107
Study 27699634 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous plasma-derived, pasteurized, nanofiltered C1-inhibitor concentrate (pnfC1-INH; Berinert)
Number of subjects: 27
Study 27701169 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostics time allocation
Number of subjects: 810
Study 27701169 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment time allocation
Number of subjects: 810
Study 27701169 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultation time allocation
Number of subjects: 810
Study 27701653 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 27702612 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 retinal images of acceptable quality
Number of subjects: 1257
Study 27702612 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 retinal images of acceptable quality
Number of subjects: 1257
Study 27702612 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 or fewer retinal images of acceptable quality
Number of subjects: 1257
Study 27702612 — intervention group
Group type: EXPERIMENTAL
Intervention: Any quality images
Number of subjects: 1257
Study 27703758 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote cognitive-behavioural therapy (CBT) - 6-12 sessions
Number of subjects: 144
Study 27703758 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 144
Study 27703774 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic self-transcending meditation (ASTM) training programme for 12 weeks
Number of subjects: 0
Study 27703774 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 0
Study 27704266 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib 12 mg once daily (QD)
Number of subjects: 46
Study 27706177 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time shear wave elastography (2D-SWE)
Number of subjects: 2251
Study 27706177 — intervention group
Group type: COMPARATOR
Intervention: Transient elastography by M probe (TE-M)
Number of subjects: 2251
Study 27706467 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimarker risk score based on cardiac troponin I, N-terminal pro-B-type natriuretic peptide, and d-dimer levels at baseline.
Number of subjects: 4880
Study 27706467 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimarker risk score added to CHA2DS2-VASc score.
Number of subjects: 4880
Study 27706467 — intervention group
Group type: EXPERIMENTAL
Intervention: Each biomarker (cardiac troponin I, N-terminal pro-B-type natriuretic peptide, d-dimer) at baseline.
Number of subjects: 4880
Study 27707436 — intervention group
Group type: EXPERIMENTAL
Intervention: PAP therapy
Number of subjects: 59
Study 27707688 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated, clinic-based care management approach
Number of subjects: 0
Study 27707688 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped-care approach targeting interventions
Number of subjects: 0
Study 27707754 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnT
Number of subjects: 2782
Study 27707754 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnI
Number of subjects: 2782
Study 27707765 — intervention group
Group type: EXPERIMENTAL
Intervention: STEBVax (recombinant staphylococcal enterotoxin B protein vaccine) at doses ranging from 0.01 μg to 20 μg
Number of subjects: 28
Study 27707765 — intervention group
Group type: EXPERIMENTAL
Intervention: STEBVax (2.5 μg to 20 μg)
Number of subjects: 28
Study 27707805 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet)
Number of subjects: 1002
Study 27707805 — intervention group
Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acid (MUFA) levels above the median
Number of subjects: 1002
Study 27707807 — intervention group
Group type: EXPERIMENTAL
Intervention: Oka/Merck varicella vaccine
Number of subjects: 240
Study 27708721 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype-based personalised nutrition advice
Number of subjects: 0
Study 27708721 — intervention group
Group type: COMPARATOR
Intervention: General healthy eating advice
Number of subjects: 0
Study 27708788 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 45
Study 27708788 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcaserin
Number of subjects: 45
Study 27708788 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of LLLT and lorcaserin
Number of subjects: 45
Study 27708788 — intervention group
Group type: COMPARATOR
Intervention: LLLT
Number of subjects: 45
Study 27708828 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision-making (SDM) framework for care planning, implemented by trained professional caregivers in nursing homes.
Number of subjects: 0
Study 27709460 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent treatment with the proton pump inhibitor pantoprazole (DE-P)
Number of subjects: 117